To investigate the prevalence of H. Pylori infection and antibiotic resistance in patients with peptic ulcer.

A retrospective analysis of 429 endoscopy and H. Pylori culture results in the First People's Hospital of Hangzhou from 2012 to 2013 was conducted. The rate of H. Pylori infection in patients with peptic ulcer, and the resistance rates of H. Pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, gentamicin, furazolidone were analysed.

The positive rate of H. Pylori in people with peptic ulcer was 53.1%(228/429). The resistance rates to metronidazole, levofloxacin, clarithromycin, amoxicillin, gentamicin and furazolidone were 94.7%(216/228), 18.9%(43/228), 18.9%(43/228), 0, 0 and 0. Double antibacterial resistant rates of metronidazole and clarithromycin, metronidazole and levofloxacin were 18.0%(41/228)and 17.1%(39/228). Triple antibacterial resistant percentage of levofloxacin+ metronidazole+ clarithromycin was 8.3%(19/228). The resistance rate of clarithromycin in 43 patients who were also resistant to levofloxacin was 46.5%(20/43), while the resistance rate of clarithromycin in 185 patients who were also sensitive to levofloxacin was 12.4%(23/185)with significant difference(χ²=26.480, P=0.000). A positive association between the resistance to levofloxacin and to clarithromycin was found.

The H. Pylori infection is closely related to the occurrence of peptic ulcer. Without the basis of culture results in patients with H. Pylori positive, amoxicillin, gentamicin and furazolidone could be the first choices in clinical, because of their low resistance rates. Clarithromycin can be used as an alternative.

Helicobacter pylori; Peptic ulcer; Resistance rate; Multiple resistance